Can a smartphone app help melanoma patients avoid severe side effects from immunotherapy?
NCT ID NCT07660666
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether having melanoma patients regularly report their symptoms through an electronic tool, combined with quick access to specialist care, can improve the management of side effects from immune checkpoint inhibitors. These drugs can cause immune-related side effects that range from mild to life-threatening. The trial enrolls 50 patients starting standard immunotherapy, along with their caregivers, to see if this monitoring approach is feasible and helps catch problems early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
electronic patient-reported outcomes tool and patient navigation
What this could lead to
If successful, this approach could help doctors catch and treat immunotherapy side effects earlier, potentially reducing severe complications and treatment interruptions.
What could go wrong
This is a small feasibility study (50 participants) focused on whether the process works, not yet on proving it improves outcomes. Results may not apply to all melanoma patients or other cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact